The sesquiterpene (−)Englerin A (EA) is an organic compound from the plant Phyllanthus engleri which acts via heteromeric TRPC4/C1 channels to cause cytotoxicity in some types of cancer cell but not normal cells. Here we identified selective cytotoxicity of EA in human synovial sarcoma cells (SW982 cells) and investigated the mechanism. EA induced cation channel current (Icat) in SW982 cells with biophysical characteristics of heteromeric TRPC4/C1 channels. Inhibitors of homomeric TRPC4 channels were weak inhibitors of the Icat and EA-induced cytotoxicity whereas a potent inhibitor of TRPC4/C1 channels (Pico145) strongly inhibited Icat and cytotoxicity. Depletion of TRPC1 converted Icat into a current with biophysical and pharmacological properties of homomeric TRPC4 channels and depletion of TRPC1 or TRPC4 suppressed the cytotoxicity of EA. A Na+/K+-ATPase inhibitor (ouabain) potentiated EA-induced cytotoxicity and direct Na+ loading by gramicidin-A caused Pico145-resistant cytotoxicity in the absence of EA. We conclude that EA has a potent cytotoxic effect on human synovial sarcoma cells which is mediated by heteromeric TRPC4/C1 channels and Na+ loading.
Natural products have served as a source of chemical compounds for therapeutics. The sesquiterpene (−)Englerin A (EA) was discovered as a potent and selective inhibitor of renal cancer growth1 and it was later suggested that EA has anti-tumor activity via activation of a novel type protein kinase C (PKC), PKCθ2. In contrast, our previous studies have suggested that EA is a potent and selective activator of canonical transient receptor potential channel 4 (TRPC4) and 5 (TRPC5), and we have proposed that EA causes anti-tumor cell activity by Na+ loading into cells through heteromeric TRPC4/C1 channels3,4. Although Carson et al. have also shown that EA activates TRPC4 and TRPC5 to inhibit tumor cell growth5, a diterpene ester, tonantzitlolone can cause cytotoxicity in renal cancer cells via the activation of PKCθ6. Moreover, it is shown that EA modifies lipid metabolism and causes ER stress in renal cancer cells7. Therefore, it is widely discussed whether EA has multiple actions or a primary target after which follow multiple downstream mechanisms8. Although it has been recently shown that application of EA elevates cytosolic Ca2+ concentration in tumor and non-tumor cells, the large component of the elevation was relatively resistant to conventional inhibitors of TRPC4 and TRPC5, ML204 and clemizole (Clm)9,10.
The canonical transient receptor potential (TRPC) family, a sub family of the TRP superfamily, form cation channels as functional tetramers. Among the seven TRPCs, TRPC1, TRPC4, and TRPC5 are classified into the same TRPC subtype and they can compose either homotetrameric channels of TRPC4 or TRPC5 or heterotetrameric channels such as TRPC4/C1 and TRPC5/C111,12,13. Since TRPC4 and TRPC5 are involved in diverse cellular functions (TRPC4: intestinal motility14, cardiac remodeling15, and visceral pain sensation16; TRPC5: neurite growth17, fear-related behavior18), they are potential targets of drugs to address dysfunction in these biological systems. However, the physiological functions of TRPC4 and TRPC5 are not fully understood at least in part because potent and selective pharmacological tools against TRPC1, TRPC4, and TRPC5 are limited, in particular blockers against heteromeric TRPC4/C1 and TRPC5/C1 channels have been lacking. However we recently reported that Pico145 is a powerful tool as a potent and selective inhibitor against heteromeric TRPC4/C1 and TRPC5/C1 as well as homometic TRPC4 and TRPC519.
In the present study we report on cytotoxicity of EA to human synovial sarcoma SW982 cells. Synovial sarcoma, which accounts for 10–20% of soft-tissue sarcomas in adolescents and young adults, is a malignant neoplasm at almost any anatomic sites20. Although synovial sarcoma is moderately sensitive to cytotoxic chemotherapy with drugs like ifosfamide and anthracyclines21,22, drug resistance during the treatments has become more common. Hence, novel therapeutic strategies and new cytotoxic drugs are awaited. Based on the result of our study, we propose that heteromeric TRPC4/C1 is a primary target of EA for a potent anti-human synovial sarcoma cell effect mediated via Na+ loading caused by sustained channel activation coupled with insufficient compensation by Na+/K+-ATPase.
Screening of EA-sensitive human cells
We first explored several human types of cell which express TRPC4 mRNA and respond to EA. We screened eight different types of tumor and non-tumor cells derived from human tissues by evaluating the TRPC4 mRNA gene expression with quantitative PCR (supplementary Fig. 1a) and measuring the functional expression of Ca2+-permeable TRPC4 and/or TRPC5 with Ca2+-response to 30 nM EA (supplementary Fig. 1b). Although among eight different types of cells employed, HaCaT, OUMS, HEK, and SW982 cells expressed TRPC4 mRNA transcripts more abundantly than IMR32, Caco2, A549, and PC3 cells, only SW982 cells significantly responded to 30 nM EA in Ca2+-measuring studies (0.57 ± 0.04 ΔF340/F380, six independent experiments, supplementary Fig. 1b and see an inset of supplementary Fig. 1b), suggesting that EA should target SW982 cell-viability.
Concentration- and time-dependent EA-induced cell-death in SW982 cells
Since an exposure to EA effectively caused cell-death in a renal cancer cell line A498 (A498) and a breast cancer cell line Hs578T (Hs578T), both of which had an EA-induced activation of Icat3,4, we next examined whether EA treatments cause any cell-death in SW982 cells (Fig. 1). As shown in Fig. 1a and b, treatments with EA for 24 and 48 h markedly reduced the cell-viability in SW982 cells in a concentration-dependent manner, whereas the treatments had no effects on viability of HaCaT, Caco2, A549, and PC3 cells. Moreover, the exposure of SW982 cells to EA at 30 nM reduced the cell-viability in a time-dependent manner (Fig. 1c), demonstrating that EA potently and selectively causes cell-death in SW982 cells. On the other hand, pretreatment of SW982 cells with 50 μM ML204, a putative inhibitor of TRPC4 and TRPC5 (IC50 against TRPC4 and TRPC5 is ~1 μM and ~5 μM, respectively23), only in part attenuated the EA-induced cell-death (Fig. 1d), suggesting that ML204 is an effective but not efficient inhibitor for EA-induced cell-death in SW982 cells.
Expression of TRPC subfamily TRPC1, TRPC4, and TRPC5 in SW982 cells
An explanation for why ML204 is only a mild inhibitor of EA-induced cell-death is that heteromeric channel composition with TRPC1 and TRPC4 (TRPC4/C1) and/or TRPC1 and TRPC5 (TRPC5/C1) forms the EA-induced Icat in SW982 cells because TRPC1-containing channels are only weakly sensitive to ML20419. Therefore, we next examined expression of TRPC5 as well as TRPC1 and TRPC4 in SW982 cells. As shown in Fig. 2a and b, RT-PCR and quantitative PCR analysis revealed that TRPC1 and TRPC4 mRNA transcripts were clearly detected, while those of TRPC5 were not. Moreover, the expression level of TRPC4α isoform was more abundant than that of TRPC4β isoform in SW982 cells (Fig. 2c). These suggest that TRPC1 and TRPC4 are abundant in SW982 cells at mRNA levels.
Biophysical properties of EA-induced Icat composed of homo- and heteromeric channel with TRPC1, TRPC4, and TRPC5
In our previous study, EA potently activated both homomeric TRPC4β and heteromeric TRPC1 and TRPC4β3. However, it is not determined yet that EA can also activate channels with homomeric TRPC4α and heteromeric TRPC1 and TRPC4α (TRPC4α/C1). Therefore, we tested effects of EA on homomeric TRPC4α and heteromeric TRPC4α/C1, both of which were heterologously expressed in HEK cells. As comparisons, we also examined effects of EA on homomeric TRPC5 and heteromeric TRPC5/C1, both of which were used in our previous studies3,19. When 100 nM EA was applied to homomeric TRPC4α and heteromeric TRPC4α/C1 in whole-cell and excised outside-out patch configurations, the large amplitude of Icat was activated in which the current-voltage relationship (I-V) had a typical chair- and ladle-shape, respectively (Fig. 3b–f). In contrast, application of 100 nM EA to HEK cells expressing TRPC1 induced a tiny Icat which may be explained by endogenous channels (Fig. 3a and f). Vigorous internal dialysis with 10 mM EGTA, which may potentiate TRPC1-dependent currents, had no effect on EA-induced Icat in HEK cells with TRPC1 (Fig. 3f). Quantitative analysis of each current amplitude ratio between +80 and −80 mV revealed that both heteromeric TRPC4α/C1 and TRPC5/C1 have significantly larger rectification than homomeric TRPC4α and TRPC5 in whole-cell and excised outside-out patch configurations and these relatively large rectifications may be a potential characteristic of the heteromeric composition of these channels.
Pharmacological properties of EA-induced Icat composed of homo- and heteromeric channel with TRPC1 and TRPC4
Pharmacological profiles of homomeric TRPC4α and heteromeric TRPC4α/C1 were tested. Here we used two putative inhibitors against TRPC4, ML204 and Clm, whose IC50 values against TRPC4 were reported to be ~1 μM and ~6 μM, respectively23,24. Once the current amplitude at +80 mV had reached or was close to the steady-state in response to 100 nM EA, each cell was exposed to the inhibitors. As shown in Fig. 4a and b, 5 μM ML204 effectively inhibited homomeric TRPC4α, whereas it was much less effective against heteromeric TRPC4α/C1 (Fig. 4c and d). When 50 μM ML204 was applied, the inhibition of heteromeric TRPC4α/C1 was significant but less strong in comparison with homomeric TRPC4α (Fig. 4a,c and i). Another TRPC4 inhibitor Clm showed similar pharmacological profiles to ML204 (Fig. 4e–h): 50 μM Clm inhibited heteromeric TRPC4α/C1 less potently than homomeric TRPC4α (Fig. 4i). These results suggest that both ML204 and Clm are not potent inhibitors against heteromeric TRPC4α/C1, and in particular inward Icat composed of the heteromer seems resistant to even 50 μM ML204 and Clm.
Biophysical and pharmacological properties of EA-induced Icat in SW982 cells
In Fig. 5, we applied EA to SW982 cells which were voltage-clamped under whole-cell conditions. EA at 100 nM activated Icat which had a clear ladle shape I-V (Fig. 5a and b). Moreover, the EA-induced current amplitude ratio between +80 and −80 mV was 2.13 ± 0.16 (n = 21) in SW982 cells, suggesting that the EA-induced Icat is composed of heteromeric TRPC4/C1. EA-induced Icat was resistant to both ML204 and Clm at 5 μM (Fig. 5a,e and g), while it was in part but significantly reduced by these inhibitors at 50 μM (Fig. 5c–g). These biophysical and pharmacological profiles of the EA-induced Icat suggest that EA treatment can activate heteromeric TRPC4/C1 in SW982 cells and that ML204 and Clm have limited usefulness as agents to test the importance of TRPC4/C1 in SW982 cell-viability. Therefore, we next used a gene knock-down technique to reduce TRPC1 and TRPC4 protein expressed in SW982 cells (Figs 6 and 7).
EA-induced Icat and cell-death in SW982 cells depleted of TRPC1 and TRPC4
After SW982 cells were treated with sc-RNA and si-TRPC1 for 40–72 h, 100 nM EA was applied to activate Icat. Compared with a SW982 cell treated with sc-RNA (Fig. 6a), a cell with si-TRPC1 had a clear EA-induced chair-shape I-V, which is typical for homomeric TRPC4 (Fig. 6b). Moreover, the current amplitude of Icat in SW982 cells with si-TRPC1 was markedly reduced in comparison to that with sc-RNA (Fig. 6c) and the current ratio between −80 and +80 mV was significantly reduced to 1.68 ± 0.21 (n = 10) (Fig. 6d). Moreover, 5 μM ML204 effectively reduced Icat in SW982 cells with si-TRPC1 and the inhibition of Icat by 50 μM ML204 was significantly larger than that with sc-RNA (Fig. 6e–i). In contrast, when SW982 cells were treated with si-TRPC4, 100 nM EA failed to activate Icat (Fig. 7a–e), suggesting that TRPC1 does not form a functional channel in SW982 cells. We also examined effects of EA on cell-viability of SW982 cells in which either TRPC1 or TRPC4 was knocked-down by si-RNAs (Fig. 7f and g). When SW982 cells were treated with si-TRPC1, EA-induced cell-death was inhibited but still significant (Fig. 7f). In contrast, in SW982 cells treated with si-TRPC4, EA-induced cell-death was abolished (Fig. 7g). These data indicate that EA still activates a small size of Icat composed of homomeric TRPC4 in SW982 cells treated with si-TRPC1 (Fig. 6b) and hence EA can still cause death in these cells (Fig. 7f).
Effects of Pico145 on EA-induced Icat and cell-death in SW982 cells
The gene-expression knock-down technique with si-RNAs is a powerful tool but may have a disadvantage of off-target effects by which expression of some proteins unrelated to the target gene are influenced25. To further confirm that the primary target of EA for cell-death in SW982 cells is heteromeric TRPC4/C1, our next maneuver involved Pico145, a novel potent inhibitor against heteromeric TRPC4/C1, which we have recently reported19. As shown in Fig. 8a–c, EA-induced Icat in SW982 cells was significantly inhibited in the presence of 10 nM Pico145, suggesting that Pico145 is a potent inhibitor against heteromeric TRPC4/C1 in SW982 cells. Pretreatment of SW982 cells with Pico145 between 0.1 and 10 nM in the absence of EA had little effect on the cell-viability (Fig. 8d). On the other hand, although the treatment of SW982 cells with 30 nM EA alone and together with 1 nM Pico145 caused substantial cell-death, the combination of 30 nM EA with 10 nM Pico145 failed to cause cell-death, strongly supporting the hypothesis that the primary target of EA in the cell-death is heteromeric TRPC4/C1.
We have previously shown that EA-evoked cytotoxicity against cancer cells is explainable by Na+ loading into cells via activation of TRPC4/C14. Therefore, we next examined whether Na+ loading is involved in EA-evoked cytotoxicity of SW982 cells. As shown in Fig. 8e, EA-induced cell-death was significantly potentiated by the pretreatment of SW982 cells with a Na+-pump inhibitor ouabain (10 nM) as previously reported in other cells4. Moreover, a Na+ loading ionophore, gramicidin-A effectively caused the cell-death of SW982 cells in a concentration-dependent manner (Fig. 8f), which was resistant to 10 nM Pico145 treatments (Fig. 8g). Furthermore, when Na+ in the bathing solution was reduced to 87.5 mM by the replacement with the larger non-permeant cation N-methyl-D-glucamine (NMDG), EA-evoked cytotoxicity of SW982 cells was significantly inhibited: in particular, the cytotoxicity by 6 h EA-treatment was abolished (Fig. 8h). In contrast, the replacement itself (in the absence of EA) had little effect on each cell viability (94.9 ± 1.0%, 97.4 ± 1.0%, and 91.2 ± 1.5% cell viability of the control by the replacement for 6, 12, and 24 h, respectively). Since a large component of EA-evoked cytotoxicity for 24 h was relatively resistant to the reduction of Na+, we next tested the possible involvement of Ca2+ overload into cells by EA. However, addition of 1 mM EGTA to the bathing solution with 1.2 mM Ca2+ did not restore the EA-evoked cytotoxicity for 6 and 24 h (Fig. 8i). The addition of EGTA in the absence of EA had little effect on cell viability (94.2 ± 0.7% and 97.5 ± 1.4% cell viability of the control for 6 and 24 h). These results strongly suggest that Na+ loading is cytotoxic for SW982 cells.
In the present study we found that treatment of synovial sarcoma SW982 cells with EA effectively causes rapid and selective cytotoxicity in a concentration- and time-dependent manner. Biophysical, pharmacological, gene expression knocking-down and Na+ loading studies suggested that EA-induced cell-death is due to Na+ loading into cells via sustained activation of heteromeric TRPC4/C1 channels which is insufficiently compensated by Na+/K+-ATPase activity.
EA is a sesquiterpene extracted from Phyllanthus engleri. Although EA is a potent inhibitor of renal cancer cell growth, there are wide discussions regarding the mechanism involved2,3,4,5,6,7,26,27,28. In this study, we found that EA effectively caused cell-death in SW982 cells. In contrast, EA even at 100 nM had no effects on cell-viability of HaCat, Caco2, A549, and PC3 cells. Since 30 nM EA markedly reduces the cell-viability of SW982 cells to 10–20% for 24–48 h treatments, EA targets a soft-tissue sarcoma SW982 cell which expresses a potential functional molecule for EA. Similarly, EA caused cell-death of Ewing sarcoma cells, another soft-tissue sarcoma cell type9. On the other hand, although native HEK cells also expressed TRPC4 mRNA transcripts (supplementary Fig. 1a), these cells had no Ca2+ response to EA. It is possible that the full-length TRPC4 protein is not expressed in HEK cells. Consistently, control HEK cells were resistant to EA in our previous studies3,4.
A few molecular targets for potent EA cancer cell-death have been proposed: PKCθ2, TRPC4/C1 or TRPC43,5, and sphingolipids7. High concentration of EA (>1 μM) blocks voltage-dependent L-type Ca2+ channels via an interaction with dihydropyridine binding sites26, but this effect is unlikely to be relevant to the cancer cell cytotoxic action of EA. EA-induced cancer cell-death was in part resistant to a TRPC4 inhibitor ML204 even at high concentrations (>50 μM5,9), suggesting that EA has multiple targets. Consistently, half of EA-induced cell-death in SW982 cells was resistant to 50 μM ML204 (Fig. 1d). Nevertheless, our present results support that EA mainly targets TRPC4/C1 in SW982 cells: it is found that ML204 is a poor inhibitor against heterometic TRPC4/C1 heterologously expressed in HEK cells and endogenously expressed in SW982 cells; a gene-knock down of TRPC4, an essential unit for channel function, abolished EA-induced Icat and cell-death in SW982 cells; pretreatment of SW982 with Pico145, a potent inhibitor of heteromeric TRPC4/C1, abolished EA-induced Icat and cell-death in SW982 cells. However, we cannot exclude the possibility of involvement of PKCθ and/or lipids in EA-induced cancer cell-death. Although the present study clearly showed the heteromeric TRPC4/C1 channel composition in SW982 cells, the stoichiometry is unknown. Since the mRNA expression of TRPC1 was more abundant than that of TRPC4 (Fig. 2b) and si-TRPC1 treatment reduced the EA-induced current amplitude of SW982 cells to 20% of the control (Fig. 6c), the involvement of one subunit of TRPC4 in the functional heterotetrameric TRPC4/C1 channel may be preferred by these cells.
We have recently proposed that Na+ loading into cells plays an important role in the underlying mechanism of EA-induced cancer cell-death4. Consistently, our present results support this mechanism: pretreatment of SW982 cells with a Na+ loading agent, ouabain substantially potentiated EA-induced cell-death. Moreover we provide the new information that application of the Na+ loading agent, gramicidin-A, caused cell-death in SW982 cells in a concentration-dependent manner. Gramicidin-A induced cell-death was totally resistant to Pico145 (Fig. 8g), importantly suggesting that Na+ loading itself is cytotoxic for cancer cells even without activation of TRPC4/C1. It is consistent that gramicidin-A treatment caused cell-death in several types of renal cancer cells29. On the other hand, the results were slightly complicated for experiments in which EA-induced cytotoxicity was tested in the bathing solution with lower Na+ concentration: the EA-induced cytotoxicity was abolished in 6 h treatment while in part sensitive to the reduction of Na+ in 12 and 24 h treatments. Since 87.5 mM Na+ was still present in the bathing solution under the present experimental conditions, the longer EA treatments may cause sufficient Na+ entry for cell-death. Alternatively, intracellular K+ loss as well as Ca2+ overload might be involved in EA-induced cytotoxicity. However, as previously described4, Ca2+ overload plays a minor role in EA-induced cytotoxicity of synovial sarcoma because addition of EGTA did not inhibit the EA-induced cell-death (Fig. 8i). Nevertheless, we cannot exclude the possibility that in later phase after exposure to EA, Na+-independent cytotoxicity might be unmasked. The mechanisms by which Na+ loading mediates cytotoxicity are not determined. Excess Na+ loading may deplete cellular ATP by forcing Na+/K+-ATPase into overdrive and inhibit a Na+-dependent amino acid transporter (system ASC transporter 2 (ASCT2)30) by reducing Na+ gradient. It is shown that ASCT2 activity is important for cancer cell proliferation31.
Synovial sarcoma accounts for 10–20% of soft-tissue sarcomas in adolescents and young adults20. Although synovial sarcoma is moderately sensitive to cytotoxic chemotherapy, drug resistance during the treatment has become more common and introduction of new drugs is clinically awaited. Since synovial sarcoma SW982 is highly sensitive to EA, EA may be promising as the basis for new agents for the treatment. Interestingly, among soft-tissue sarcomas, several Ewing sarcomas are also sensitive to EA9. For clinical application of EA and its analogues to these soft-tissue sarcomas, we should draw a final conclusion about EA-targets which have a strong connection to cancer pathology.
In conclusion, our results reveal that EA exhibits anti-tumor cell activity in SW982 cells and that heteromeric TRPC4/C1 channels in these cells are a critical target of EA. In addition, EA-induced cell-death in SW982 cells is mediated by Na+ loading via activation of heteromeric TRPC4/C1 channels coupled with insufficient Na+/K+-ATPase activity. Thus, EA may be a potential anti-tumor agent against soft-tissue synovial sarcoma and its effect may be potentiated by Na+/K+-ATPase inhibitors such as digoxin. Further study is needed to explore the therapeutic effects of EA and EA analogues on human samples of synovial sarcoma and tumors in vivo.
The following drugs were used: (−)Englerin A (EA, AppliChem, Darmstadt, Germany), clemizole hydrochloride (Clm, BioVision, Milpitas, CA), 4-methyl-2-(1-piperidinyl)-quinoline (ML204, Tocris Bioscience, Bristol, United Kingdom), ouabain (Sigma/Aldrich, St. Louis, MO), Pico14519, and gramicidin-A (Sigma/Aldrich). Each drug except Pico145 was dissolved in the vehicle recommended by the manufacturer. Pico145 was dissolved in 100% DMSO to make 10 μM stoc19.
Immortal human skin keratinocytes (HaCaT, American Type Culture Collection: ATCC, Manassas, VA), human chondrosarcoma (OUMUS, Health Science Research Resources Bank: HSRRB, Osaka, Japan), human colorectal adenocarcinoma (Caco2, DS Pharma Biomedical Co., Osaka, Japan), human alveolar A549 (A549, DS Pharma Biomedical Co., Osaka Japan), human prostate adenocarcinoma (PC3, kindly gifted by Professor Ohya), human synovial sarcoma SW982 (SW982, ATCC), human embryonic kidney 293 cell-line (HEK, HSRRB), and human neuroblastoma IMR32 (IMR32, DS Pharma Biomedical Co.) were maintained in culture medium recommended by the manufacturer. All culture medium was supplemented with 10% heat-inactivated FCS (GIBCO, Waltham, MA), streptomycin (100 μg/mL, Meiji Seika Pharma Co., Ltd., Tokyo, Japan), and penicillin G (100 U/mL, Meiji Seika Pharma Co., Ltd.).
Recombinant expression of TRPCs in HEK cells
Partially confluent HEK cells (40–60% confluency) were transfected with the pcDNA3.1 (TRPC4α for screening in supplementary Fig. 1), pIRES2-AcGFP1 (TRPC1, TRPC4α, and TRPC5) and pIRES2-DsRed-Express2 (TRPC4α and TRPC5 for heteromeric channel expression) plasmids containing human TRPC1, TRPC4α, and TRPC5 cloned by ourselves, respectively, using lipofectamine 3000 (ThermoFisher Scientific, Yokohama, Japan). All constructs were sequenced. All experiments were performed within 48 h after transfection.
RT-PCR amplification for TRPC1, TRPC4, TRPC4α, TRPC4β, and TRPC5 was performed as described previously32. The thermal cycler program used for PCR amplification included a 30 s denaturation step at 94 °C, a 30 s annealing step at 55 °C, and a 30 s primer extension step at 72 °C for 30 and 33 cycles using an ABI 2720 thermal cycler (Applied Biosystems, Foster City, CA). The amplified products were separated on 1.5% agarose gels in Tris acetate/EDTA buffer, visualized with 1 μg/ml ethidium bromide, and assessed on FAS III (TOYOBO, Osaka, Japan). Oligonucleotide sequences of primers specific for human TRPC1, TRPC4, TRPC4α, TRPC4β, and TRPC5 are shown in supplementary Table 1.
Real-time quantitative PCR was done with the use of SYBR Green Chemistry on a Thermal Cycler Dice Real Time System (Takara Bio, Inc., Kusatsu, Japan) as described previously32. Transcriptional quantification of gene products was normalized to that of β-actin and each cDNA sample was tested in triplicate. The program used for quantitative PCR amplification included a 30 s activation of Ex Taq™ DNA polymerase at 95 °C, a 15 s denaturation step at 95 °C, a 60 s annealing and extention step at 60 °C (for 45 cycles), and a dissociation step (15 s at 95 °C, 30 s at 60 °C and 15 s at 95 °C). Oligonucleotide sequences of primers specific for human TRPC1, TRPC4, TRPC5, and β-actin are shown in supplementary Table 1.
Patch clamp experiments
Whole-cell and excised single channel recording experiments were performed as described previously33. The resistance of pipettes was 3–5 MΩ when filled with pipette solution. A Cs+ rich pipette solution contained [in mM] Cs-aspartate 110, CsCl 30, MgCl2 1, HEPES 10, EGTA 1 or 10, and Na2ATP 2 [adjusted to pH 7.2 with CsOH]. Membrane currents and voltage signals were digitized using an analogue-digital converter (PCI6229, National Instruments Japan, Tokyo, Japan) driven by WinWCPV4.5 for data acquisition and analysis of whole-cell currents and excised outside-out single channel currents (developed by Dr. John Dempster, University of Strathclyde, UK). The liquid junction potential between the pipette and bath solutions (−10 mV) was corrected. A ramp voltage protocol from −110 mV to + 90 mV for 400 ms was applied every 5 s from a holding potential of −10 mV. A leak current component was not subtracted from the recorded currents. A standard HEPES-buffered bathing solution (SBS [in mM]: NaCl 137, KCl 5.9, CaCl2 2.2, MgCl2 1.2, glucose 14, HEPES 10 [adjusted to pH 7.4 with NaOH]) was used. All experiments were performed at 25 ± 1 °C.
Measurement of Ca2+ fluorescence ratio
Cells, which were loaded with 10 μM Fura2-AM (Dojindo, Kumamoto, Japan) in the SBS for 30 min at room temperature, were superfused with SBS for 10 min and then Fura-2 fluorescence signals were measured at 0.1 Hz using the Argus/HisCa imaging system (Hamamatsu Photonics, Hamamatsu, Japan) driven by Imagework Bench 6.0 (INDEC Medical Systems, Santa Clara, CA). In each analysis, a whole cell area was chosen as a region of interest to average the fluorescence ratio.
Specific knockdown of TRPC1 and TRPC4 by RNA Interference
The sequence of the stealth short interference RNA (siRNAs) duplex oligoribonucleotides against human TRPC1 (si-TRPC1, GenBank Accession No. NM_001251845.1, Invitrogen, Carlsbad, CA) and TRPC4 (si-TRPC4, GenBank Accession No. NM_003306.1 Invitrogen) is 5′-CCUUUGCCCUCAAAGUGGUUGCUCA-3′ for sense strand and 5′-UGAGCAACCACUUUGAGGGCAAAGG-3′ for antisense strand, and 5′-GGAAGAACUGCUCUCCUCAUUGCAA-3′ for sense strand, and 5′-UUGCAAUGAGGAGAGCAGUUCUUCC-3′ for antisense strand, respectively. As a negative control for the siRNAs treatment, Medium GC Stealth RNAi Negative Control Duplex (sc-RNA, Invitrogen) was used. The cells in a 35-mm dish and in 24-well plate were washed with fresh culture medium without antibiotics 3 h prior to transfection. The si-RNAs or sc-RNA (20 µM, 6 µl for 35-mm dish and 1.5 μl for 24-well plate) and Lipofectamine RNAiMAX (5 µl for 35-mm dish and 1.25 μl for 24-well plate, Invitrogen) were diluted in 200 µl (35-mm dish) and 50 μL (24-well plates) Opti-MEM (Invitrogen), respectively. The diluted si-RNAs or sc-RNA solution and the diluted Lipofectamine RNAiMAX solution were mixed. These two mixtures were combined and incubated for 20 min at room temperature for complex formation. The entire mixture was added to the cells, resulting in a final concentration of 50 nM for both si-RNAs and sc-RNA. The cells were incubated for 40–72 h in a CO2 chamber.
WST-1 cell-viability assay
Cells were seeded onto 24-well plates 24 h prior to WST-1 measurements (1 × 104 SW982, 1 × 104 HaCaT, 4 × 104 Caco2, 5 × 103 A549, and 1 × 104 PC3 cells). The cell proliferation reagent WST-1 (Roche Applied Science, Penzberg, Germany) was used in accordance to the manufacturer’s instructions. Reduction of the tetrazolium salt WST-1 to formazan by mitochondrial dehydrogenases was determined by absorbance measurement at 450 nm (DXT880 Multimode Detector, Beckman Coulter, Brea, CA). Cell-death, loss of mitochondrial dehydrogenase activity, was inferred from a decrease in this reaction. Background absorbance at the reference wavelength 620 nm was subtracted. Each cell-sample was tested in duplicate or triplicate and pooled data were summarized in independent experiments. When the cell-viability was assayed in lower Na+ and Ca2+ bathing solution (Fig. 8h and i), Krebs buffer solution was used (Krebs [in mM]: NaCl 125, KCl 3.8, CaCl2 1.2, MgSO4 1.5, glucose 8, KH2PO4 1.2, and NaHCO3 25 (pH 7.4)).
Data are expressed as the mean ± SEM except supplementary Fig. 1b (mean ± SD). Statistical significance between two groups and among multiple groups was examined using paired or unpaired Student’s t-tests, and ANOVA or Tukey’s test, respectively, which were two-tailed (Origin J9.1, LightStone, Tokyo, Japan). For all tests, P values less than 0.05 were considered statistically significant.
Ratnayake, R., Covell, D., Ransom, T. T., Gustafson, K. R. & Beutler, J. A. Englerin A, a selective inhibitor of renal cancer cell growth, from Phyllanthus engleri. Org. Lett. 11, 57–60 (2009).
Sourbier, C. et al. Englerin A stimulates PKCtheta to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 23, 228–237 (2013).
Akbulut, Y. et al. (−)Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew. Chem. Int. Ed. Engl. 54, 3787–3791 (2015).
Ludlow, M. J. et al. (−)Englerin A-evoked cytotoxicity is mediated by Na+ influx and counteracted by Na+/K+-ATPase. J. Biol. Chem. 292, 723–731 (2017).
Carson, C. et al. Englerin A agonizes the TRPC4/C5 cation channels to inhibit tumor cell line proliferation. PLoS One 10, e0127498, https://doi.org/10.1371/journal.pone.0127498 (2015).
Sourbier, C. et al. Tonantzitlolone cytotoxicity toward renal cancer cells is PKCtheta- and HSF1-dependent. Oncotarget 6, 29963–29974 (2015).
Batova, A. et al. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. PLoS One 12, e0172632, https://doi.org/10.1371/journal.pone.0172632 (2017).
Wu, Z. et al. Englerins: A Comprehensive Review. J Nat Prod 80, 771–781 (2017).
Caropreso, V. et al. Englerin A inhibits EWS-FLI1 DNA binding in Ewing sarcoma cells. J. Biol. Chem. 291, 10058–10066 (2016).
Beck, A. et al. Functional characterization of transient receptor potential (TRP) channel C5 in female murine gonadotropes. Endocrinology 158, 887–902 (2017).
Storch, U. et al. Transient receptor potential channel 1 (TRPC1) reduces calcium permeability in heteromeric channel complexes. J. Biol. Chem. 287, 3530–3540 (2012).
Myeong, J., Kwak, M., Hong, C., Jeon, J. H. & So, I. Identification of a membrane-targeting domain of the transient receptor potential canonical (TRPC)4 channel unrelated to its formation of a tetrameric structure. J. Biol. Chem. 289, 34990–35002 (2014).
Myeong, J. et al. The interaction domains of transient receptor potential canonical (TRPC)1/4 and TRPC1/5 heteromultimeric channels. Biochem. Biophys. Res. Commun. 474, 476–481 (2016).
Tsvilovskyy, V. V. et al. Deletion of TRPC4 and TRPC6 in mice impairs smooth muscle contraction and intestinal motility in vivo. Gastroenterology 137, 1415–1424 (2009).
Camacho Londono, J. E. et al. A background Ca2+ entry pathway mediated by TRPC1/TRPC4 is critical for development of pathological cardiac remodelling. Eur. Heart J. 36, 2257–2266 (2015).
Westlund, K. N. et al. A rat knockout model implicates TRPC4 in visceral pain sensation. Neuroscience 262, 165–175 (2014).
Greka, A., Navarro, B., Oancea, E., Duggan, A. & Clapham, D. E. TRPC5 is a regulator of hippocampal neurite length and growth cone morphology. Nat. Neurosci. 6, 837–845 (2003).
Riccio, A. et al. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell 137, 761–772 (2009).
Rubaiy, H. N. et al. Picomolar, selective, and subtype-specific small-molecule inhibition of TRPC1/4/5 channels. J. Biol. Chem. 292, 8158–8173 (2017).
Herzog, C. E. Sarcomas in adolescents and young adults: a summary of a recent symposium. J. Pediatr. Hematol. Oncol. 27, 177–178 (2005).
Spurrell, E. L., Fisher, C., Thomas, J. M. & Judson, I. R. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol. 16, 437–444 (2005).
Al-Hussaini, H. et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011, 231789, https://doi.org/10.1155/2011/231789 (2011).
Miller, M. et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J. Biol. Chem. 286, 33436–33446 (2011).
Richter, J. M., Schaefer, M. & Hill, K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol. Pharmacol. 86, 514–521 (2014).
Jackson, A. L. & Linsley, P. S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9, 57–67 (2010).
Rodrigues, T. et al. Unveiling (−)Englerin A as a modulator of L-type calcium channels. Angew. Chem. Int. Ed. Engl. 55, 11077–11081 (2016).
Sulzmaier, F. J. et al. Englerin a selectively induces necrosis in human renal cancer cells. PLoS One 7, e48032, https://doi.org/10.1371/journal.pone.0048032 (2012).
Williams, R. T., Yu, A. L., Diccianni, M. B., Theodorakis, E. A. & Batova, A. Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J. Exp. Clin. Cancer Res. 32, 57, https://doi.org/10.1186/1756-9966-32-57 (2013).
David, J. M., Owens, T. A., Barwe, S. P. & Rajasekaran, A. K. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells. Mol. Cancer Ther. 12, 2296–2307 (2013).
Utsunomiya-Tate, N., Endou, H. & Kanai, Y. Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J. Biol. Chem. 271, 14883–14890 (1996).
Fuchs, B. C. & Bode, B. P. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 15, 254–266 (2005).
Itoh, Y. et al. An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes. Am. J. Physiol. Cell Physiol. 297, C1082–1090 (2009).
Suzuki, H. et al. The NADPH oxidase inhibitor diphenyleneiodonium activates the human TRPA1 nociceptor. Am. J. Physiol. Cell Physiol. 307, C384–394 (2014).
This work was supported by Grant-in-Aid for Scientific Research to KM (26460349) from the Japan Society for the Promotion of Science. We thank Dr. J. Dempster (University of Strathclyde, UK) for developing the electrophysiology software (WinWCPV4.5). We thank Professor S Ohya (Nagoya City University, Japan) for kindly providing us PC3 cells.
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Muraki, K., Ohnishi, K., Takezawa, A. et al. Na+ entry through heteromeric TRPC4/C1 channels mediates (−)Englerin A-induced cytotoxicity in synovial sarcoma cells. Sci Rep 7, 16988 (2017). https://doi.org/10.1038/s41598-017-17303-3
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition
ACS Medicinal Chemistry Letters (2020)
Computational Biology and Chemistry (2020)
International Journal of Molecular Sciences (2020)
British Journal of Pharmacology (2019)
Medical Sciences (2019)